Pancreatitis Clinical Trial
Official title:
Tailored Hydration for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis
Verified date | November 2023 |
Source | Chonnam National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Aggressive hydration of lactated Ringer's solution has shown considerable beneficial effect in preventing post-ERCP(endoscopic retrograde cholangiopancreatography) pancreatitis. But the occurence rate of post-ERCP pancreatitis are near 10% and there are severe complications of aggressive hydration due to hypervolemia such pulmonary and peripheral edema, prolonged hospital stay and increased medical expense. Also there are no definite guidelines that suggest the duration and amount of hydration. This study evaluates the efficacy and safety of tailored hydration depending on each patient's condition that indicates the likelihood of developing post-ERCP pancreatitis.
Status | Completed |
Enrollment | 350 |
Est. completion date | October 4, 2023 |
Est. primary completion date | January 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: - All patients older than 20 years undergoing ERCP for the 1st time will be recruited Exclusion Criteria: - Age below 20 or above 80 years - Underlying severe psychiatric illness - Cardiac insufficiency (>New York Heart Association Class II heart failure) - Renal insufficiency (eGFR <30mililiter/min/1.73m2) - Respiratory insufficiency (defined as oxygen saturation < 90%) - Poorly controlled blood sugar - Ongoing hypotension including those with sepsis - Ongoing acute pancreatitis - Underlying disease of chronic pancreatitis - Clinical signs of hypervolemia - Hyponatremia (Na+ levels < 130 milliequivalent (mEq)/L)) - Hypernatremia (Na+ levels > 150mEq/L) - Hyperkalemia (5.1 mEq/dL) - Metabolic alkalosis - Past history of endoscopic sphincterectomy or endoscopic papillary balloon dilatation |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Chonnam National University Hospital | Gwangju |
Lead Sponsor | Collaborator |
---|---|
Chonnam National University Hospital | Chonbuk National University Hospital, Kwangju christian hospital, Presbyterian medical center, Wonkwang University Hospital |
Korea, Republic of,
Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, Annese V. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc. 2007 Apr;65(4):624-32. doi: 10.1016/j.gie.2006.10.030. — View Citation
ASGE Standards of Practice Committee; Anderson MA, Fisher L, Jain R, Evans JA, Appalaneni V, Ben-Menachem T, Cash BD, Decker GA, Early DS, Fanelli RD, Fisher DA, Fukami N, Hwang JH, Ikenberry SO, Jue TL, Khan KM, Krinsky ML, Malpas PM, Maple JT, Sharaf RN, Shergill AK, Dominitz JA. Complications of ERCP. Gastrointest Endosc. 2012 Mar;75(3):467-73. doi: 10.1016/j.gie.2011.07.010. No abstract available. — View Citation
Buxbaum J, Yan A, Yeh K, Lane C, Nguyen N, Laine L. Aggressive hydration with lactated Ringer's solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography. Clin Gastroenterol Hepatol. 2014 Feb;12(2):303-7.e1. doi: 10.1016/j.cgh.2013.07.026. Epub 2013 Aug 3. — View Citation
Choi JH, Kim HJ, Lee BU, Kim TH, Song IH. Vigorous Periprocedural Hydration With Lactated Ringer's Solution Reduces the Risk of Pancreatitis After Retrograde Cholangiopancreatography in Hospitalized Patients. Clin Gastroenterol Hepatol. 2017 Jan;15(1):86-92.e1. doi: 10.1016/j.cgh.2016.06.007. Epub 2016 Jun 14. — View Citation
Jeurnink SM, Poley JW, Steyerberg EW, Kuipers EJ, Siersema PD. ERCP as an outpatient treatment: a review. Gastrointest Endosc. 2008 Jul;68(1):118-23. doi: 10.1016/j.gie.2007.11.035. Epub 2008 Mar 4. — View Citation
Kerdsirichairat T, Attam R, Arain M, Bakman Y, Radosevich D, Freeman M. Urgent ERCP with pancreatic stent placement or replacement for salvage of post-ERCP pancreatitis. Endoscopy. 2014 Dec;46(12):1085-94. doi: 10.1055/s-0034-1377750. Epub 2014 Sep 12. — View Citation
Park CH, Jung JH, Hyun B, Kan HJ, Lee J, Kae SH, Jang HJ, Koh DH, Choi MH, Chung MJ, Bang S, Park SW. Safety and efficacy of early feeding based on clinical assessment at 4 hours after ERCP: a prospective randomized controlled trial. Gastrointest Endosc. 2018 Apr;87(4):1040-1049.e1. doi: 10.1016/j.gie.2017.09.021. Epub 2017 Sep 28. — View Citation
Rabago L, Guerra I, Moran M, Quintanilla E, Collado D, Chico I, Olivares A, Castro JL, Gea F. Is outpatient ERCP suitable, feasible, and safe? The experience of a Spanish community hospital. Surg Endosc. 2010 Jul;24(7):1701-6. doi: 10.1007/s00464-009-0832-5. Epub 2010 Jan 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Development of post-ERCP pancreatitis | Defined as pancreatic pain (= 3 on visual analogue numeric pain rating scale (0-10)) and serum amylase level 3 times the upper limit of normal. | 24 hours | |
Secondary | Clinical volume overload | Defined by physical findings of peripheral edema and pulmonary rales | 24 hours | |
Secondary | Hyperamylasemia | Elevated serum amylase level above than upper limit of normal | 24 hours | |
Secondary | Increased abdominal pain | Defined as an increase in abdominal pain based on the visual analogue numeric pain rating score (0-10) following the ERCP compared to the score immediately prior to the ERCP. | 24 hours | |
Secondary | Hospital stay | Whole duration of hospital admission days | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03609944 -
SpHincterotomy for Acute Recurrent Pancreatitis
|
N/A | |
Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
Completed |
NCT01441492 -
Pancreas Resection With and Without Drains
|
N/A | |
Recruiting |
NCT02196935 -
Los Angeles Prospective GI Biliary and EUS Series
|
||
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01545167 -
The North American Pancreatitis Study
|
N/A | |
Completed |
NCT04168801 -
Early Oral Refeeding in Mild Acute Pancreatitis
|
N/A | |
Recruiting |
NCT03334708 -
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
|
||
Completed |
NCT01824186 -
Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy
|
N/A | |
Terminated |
NCT00428025 -
Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients
|
Phase 4 | |
Completed |
NCT00639314 -
Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT00160836 -
Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter
|
Phase 1 | |
Completed |
NCT00999232 -
Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube
|
Phase 4 | |
Completed |
NCT00121901 -
Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?
|
Phase 3 | |
Terminated |
NCT00419549 -
Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05095831 -
EUS Shear Wave for Solid Pancreatic Lesions.
|
||
Completed |
NCT03601325 -
Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
|
||
Withdrawn |
NCT02465138 -
A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis
|
Phase 4 | |
Not yet recruiting |
NCT06133023 -
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
|
N/A | |
Recruiting |
NCT02971475 -
ESWL Versus ESWL and Endoscopic Treatment
|
N/A |